Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ad-Free, Unlimited access)​
NO CREDIT CARD REQUIRED
BBLG logo BBLG
Upturn stock ratingUpturn stock rating
BBLG logo

Bone Biologics Corp (BBLG)

Upturn stock ratingUpturn stock rating
$4.03
Last Close (24-hour delay)
Profit since last BUY-26.33%
upturn advisory
WEAK BUY
BUY since 27 days
  • BUY Advisory
  • SELL Advisory (Profit)​
  • SELL Advisory (Loss)​
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK

Upturn Advisory Summary

06/30/2025: BBLG (1-star) has a low Upturn Star Rating. Not recommended to BUY.

Upturn Star Rating

rating

Not Recommended Performance

These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.

Number of Analysts

rating

1 Analysts rated it

Very few follow this stock; limited insights, higher-risk early investing.

1 Year Target Price $22.5

1 Year Target Price $22.5

Analysts Price Target For last 52 week
$22.5Target price
Low$3.42
Current$4.03
high$22.2

Analysis of Past Performance

Type Stock
Historic Profit -76.27%
Avg. Invested days 22
Today’s Advisory WEAK BUY
Upturn Star Rating Upturn stock ratingUpturn stock rating
Upturn Advisory Performance Upturn Advisory Performance 1.0
Stock Returns Performance Upturn Returns Performance 1.0
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 06/30/2025

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 2.50M USD
Price to earnings Ratio -
1Y Target Price 22.5
Price to earnings Ratio -
1Y Target Price 22.5
Volume (30-day avg) 1
Beta 1.28
52 Weeks Range 3.42 - 22.20
Updated Date 06/30/2025
52 Weeks Range 3.42 - 22.20
Updated Date 06/30/2025
Dividends yield (FY) -
Basic EPS (TTM) -23.04

Earnings Date

Report Date -
When -
Estimate -
Actual -

Profitability

Profit Margin -
Operating Margin (TTM) -

Management Effectiveness

Return on Assets (TTM) -77.73%
Return on Equity (TTM) -129.48%

Valuation

Trailing PE -
Forward PE -
Enterprise Value -244211
Price to Sales(TTM) -
Enterprise Value -244211
Price to Sales(TTM) -
Enterprise Value to Revenue -
Enterprise Value to EBITDA 0.13
Shares Outstanding 545173
Shares Floating 537318
Shares Outstanding 545173
Shares Floating 537318
Percent Insiders 0.12
Percent Institutions 1.1

Analyst Ratings

Rating 1
Target Price 22.5
Buy -
Strong Buy 1
Buy -
Strong Buy 1
Hold -
Sell -
Strong Sell -
Strong Sell -

ai summary icon Upturn AI SWOT

Bone Biologics Corp

stock logo

Company Overview

overview logo History and Background

Bone Biologics Corp (BBLG) is a biotechnology company focused on bone regeneration technology. It was founded with the goal of developing and commercializing novel osteobiologic products for spinal fusion and fracture healing.

business area logo Core Business Areas

  • Osteobiologics Development: Focused on the development and commercialization of NBMTM (NELL-1 based matrix), a recombinant human protein therapeutic for bone regeneration.

leadership logo Leadership and Structure

The leadership team consists of experienced executives in biotechnology and orthopedics. The company structure is typical of a small, development-stage biotechnology firm, with emphasis on research, clinical development, and regulatory affairs.

Top Products and Market Share

overview logo Key Offerings

  • NELL-1 based matrix (NBMTM): NELL-1 is a recombinant human protein therapeutic designed to promote bone regeneration and spinal fusion. Currently in clinical development, it does not yet have market share. Competitors include Medtronic (MDT), Stryker (SYK), and NuVasive (NUVA), which offer bone graft substitutes and biologics.

Market Dynamics

industry overview logo Industry Overview

The orthopedic biologics market is experiencing growth driven by an aging population, increasing prevalence of spinal disorders, and demand for minimally invasive surgical techniques. The market is competitive, with both large and small companies vying for market share.

Positioning

Bone Biologics Corp is positioned as an innovator in bone regeneration, leveraging its proprietary NELL-1 technology. Its success depends on clinical trial outcomes and regulatory approvals.

Total Addressable Market (TAM)

The total addressable market for bone graft substitutes and biologics is estimated to be billions of dollars annually. BBLG is positioned to capture a portion of this market if NBMTM is successfully commercialized.

Upturn SWOT Analysis

Strengths

  • Proprietary NELL-1 technology
  • Potential for superior bone regeneration compared to existing products
  • Experienced management team

Weaknesses

  • Limited financial resources
  • Reliance on clinical trial success
  • Lack of commercialized products
  • High burn rate

Opportunities

  • Partnerships with larger orthopedic companies
  • Expansion into new indications for NELL-1
  • Favorable regulatory environment for biologics
  • Growing demand for minimally invasive spinal fusion procedures

Threats

  • Clinical trial failures
  • Competition from established players
  • Regulatory hurdles
  • Difficulty securing funding

Competitors and Market Share

competitor logo Key Competitors

  • MDT
  • SYK
  • NUVA

Competitive Landscape

Bone Biologics Corp faces intense competition from established orthopedic companies with significantly greater resources. Its competitive advantage lies in its proprietary NELL-1 technology.

Growth Trajectory and Initiatives

Historical Growth: Growth has been primarily in R&D spending and clinical trial activity.

Future Projections: Future growth depends on successful clinical trials, regulatory approvals, and commercialization of NBMTM. Analyst estimates are highly speculative at this stage.

Recent Initiatives: Recent initiatives include advancing clinical trials for NBMTM and securing additional funding.

Summary

Bone Biologics Corp is a high-risk, high-reward biotechnology company with a promising bone regeneration technology. The company's success hinges on the outcome of clinical trials and its ability to secure funding. It faces strong competition from established players in the orthopedic market and is currently in a highly developmental stage without revenue. Investors need to closely monitor clinical trial data and the company's cash position.

Peer Comparison

Sources and Disclaimers

Data Sources:

  • Company SEC filings
  • Industry reports
  • Analyst reports (when available)

Disclaimers:

This analysis is for informational purposes only and should not be considered investment advice. The information provided is based on publicly available data and may not be entirely accurate or complete. Investment decisions should be made based on thorough research and consultation with a qualified financial advisor.

Upturn AI SummarizationUpturn AI Summarization AI Summarization is directionally correct and might not be accurate.

Upturn AI SummarizationUpturn AI Summarization Summarized information shown could be a few years old and not current.

Upturn AI SummarizationUpturn AI Summarization Fundamental Rating based on AI could be based on old data.

Upturn AI SummarizationUpturn AI Summarization AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.

About Bone Biologics Corp

Exchange NASDAQ
Headquaters Burlington, MA, United States
IPO Launch date 2016-03-31
CEO & President Mr. Jeffrey Frelick
Sector Healthcare
Industry Medical Devices
Full time employees 2
Full time employees 2

Bone Biologics Corporation, a medical device company, focuses on bone regeneration in spinal fusion using the recombinant human protein. The company's lead medical device NELL-1/DBM, an osteopromotive recombinant protein that provides target-specific control over bone regeneration. It also develops NELL-1/DBM fusion device used in lumbar spinal fusion. The company's NELL-1 platform technology used in delivering enhanced outcomes in the surgical specialties of spinal, orthopedic, general orthopedic, plastic reconstruction, neurosurgery, interventional radiology, and sports medicine. It serves spine surgeons and patients with a skeletal bone defect or bone-related condition in their spine. The company has a license agreement with the UCLA Technology Development Group to develop and commercialize NELL-1 for spinal fusion applications. Bone Biologics Corporation was founded in 2004 and is headquartered in Burlington, Massachusetts.